Recruiting PHASE1/PHASE2 INTERVENTIONAL NCT06527898

Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer

Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer: a Phase II Trial

Sponsor: Anhui Provincial Hospital

Interventions hypofractionated radiotherapy with immunotherapy

Updated 3 times since 2024 Last updated: Sep 12, 2024 Started: Jul 1, 2024 Primary completion: Jul 31, 2026 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Small-cell Lung Cancer and is currently actively recruiting participants. Anhui Provincial Hospital leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Oct 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anhui Provincial Hospital

Data source: Anhui Provincial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hefei, China